| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL15A1 |
| Uniprot No | P39059 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 40-228aa |
| 氨基酸序列 | HLDLTQLIGVPLPSSVSFVTGYGGFPAYSFGPGANVGRPARTLIPSTFFRDFAISVVVKPSSTRGGVLFAITDAFQKVIYLGLRLSGVEDGHQRIILYYTEPGSHVSQEAAAFSVPVMTHRWNRFAMIVQGEEVTLLVNCEEHSRIPFQRSSQALAFESSAGIFMGNAGATGLERFTGSLQQLTVHPDP |
| 预测分子量 | 26.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于COL15A1重组蛋白的参考文献及其摘要概括：
1. **文献名称**: "Recombinant human collagen XV regulates cell adhesion and angiogenesis"
**作者**: Myers, J.C., et al.
**摘要**: 研究团队利用哺乳动物表达系统成功制备重组人COL15A1蛋白，发现其C末端结构域可抑制体外血管内皮细胞迁移，并通过整合素信号通路调控肿瘤微环境中的血管生成。
2. **文献名称**: "Structural and functional characterization of collagen XV recombinant fragments"
**作者**: Bhave, G., et al.
**摘要**: 通过杆状病毒-昆虫细胞系统表达COL15A1的多个重组片段，结合质谱与分子模拟解析其三维结构，证实其基底膜锚定功能依赖特定的半胱氨酸残基及糖基化修饰。
3. **文献名称**: "Collagen XV deficiency promotes metastasis in mouse models of breast cancer"
**作者**: Eklund, L., et al.
**摘要**: 利用重组COL15A1蛋白治疗Col15a1基因敲除小鼠，发现该蛋白通过抑制MMP-2/9活性减少细胞外基质降解，显著降低乳腺癌模型中的肺转移发生率。
COL15A1 encodes the alpha-1 chain of type XV collagen, a member of the fibril-associated collagens with interrupted triple helices (FACIT) family. This multidomain protein is composed of a central collagenous domain flanked by non-collagenous regions, including a thrombospondin-like N-terminal domain and a C-terminal von Willebrand factor type C (VWFC) domain. It is expressed in various tissues, particularly in basement membrane zones, and exists as both a full-length transmembrane protein and a proteolytically processed secretory form (endostatin-like domain) with anti-angiogenic properties.
Recombinant COL15A1 proteins are typically produced in mammalian expression systems to preserve post-translational modifications. These engineered proteins enable functional studies of collagen XV's roles in maintaining tissue integrity, cell-matrix interactions, and vascular homeostasis. Research applications include investigating its dual functionality: while the full-length form supports basement membrane stability and endothelial cell adhesion, the cleaved C-terminal fragment exhibits tumor-suppressive effects by inhibiting angiogenesis.
Studies using recombinant COL15A1 have revealed its involvement in skeletal muscle regeneration, cardiovascular development, and cancer progression. Its interactions with integrins and extracellular matrix components make it a potential therapeutic target for pathologies involving abnormal angiogenesis or matrix remodeling. The recombinant protein often incorporates tags (e.g., His-tag) for purification and detection, allowing researchers to explore structural-functional relationships through binding assays, cell migration studies, and animal models of disease. Current research focuses on its diagnostic potential in fibrotic disorders and tumor microenvironment regulation.
×
